MARKET

AKTX

AKTX

Akari
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.170
+0.030
+1.40%
After Hours: 2.290 +0.12 +5.53% 18:55 04/16 EDT
OPEN
2.150
PREV CLOSE
2.140
HIGH
2.200
LOW
2.110
VOLUME
93.87K
TURNOVER
--
52 WEEK HIGH
4.210
52 WEEK LOW
1.420
MARKET CAP
83.49M
P/E (TTM)
-2.9726
1D
5D
1M
3M
1Y
5Y
Global Atypical Hemolytic Uremic Syndrome Drug Market Outlook, Industry Analysis and Prospect 2021-2026
Apr 15, 2021 (Heraldkeepers) -- The Atypical Hemolytic Uremic Syndrome Drug market report provides a detailed analysis of global market size, regional and...
Heraldkeepers · 2d ago
Akari Down on New Drug Probe
Apr 13, 2021 (Baystreet.ca via COMTEX) -- Akari Therapeutics, Plc (NASDAQ:AKTX) fell Tuesday, a day after the FDA opened the investigational new drug...
Baystreet.ca · 4d ago
Akari Therapeutics' To Go With Pivotal Bullous Pemphigoid Study With Nomacopan
Benzinga · 5d ago
DJ Akari Therapeutics Shares Rise After Opening IND for Nomacopan
Dow Jones · 5d ago
Akari shares rise on bullous pemphigoid nomacopan late-stage study initiation
Akari Therapeutics shares jump ([[AKTX]] +22.4%) after announcing that an IND is now open with the U.S. FDA for its multicenter Phase III study with nomacopan for the treatment of
Seekingalpha · 5d ago
Akari Therapeutics Announces Initiation Of Pivotal Phase III Trial Of Nomacopan In Bullous Pemphigoid
Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Bullous Pemphigoid (BP) FDA investigational new drug application (IND) now open   Clinical sites expected to open for recruitment
Benzinga · 5d ago
Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Bullous Pemphigoid (BP)
FDA investigational new drug application (IND) now open Clinical sites expected to open for recruitment mid-2021 NEW YORK and LONDON, April 12, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovati...
GlobeNewswire · 5d ago
COVID-19 Pandemic Effect and Impact Analysis on Icca Syndrome Drug Market by 2027
Apr 07, 2021 (Market Insight Reports) -- The latest report as Icca Syndrome Drug Market acknowledges Size, Application Segment, Type, Regional Outlook,...
Market Insight Reports · 04/07 10:26
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AKTX. Analyze the recent business situations of Akari through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AKTX stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 27
Institutional Holdings: 2.52M
% Owned: 6.54%
Shares Outstanding: 38.47M
TypeInstitutionsShares
Increased
2
10.11K
New
4
210.22K
Decreased
2
1.06K
Sold Out
3
92.98K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/Director
Ray Prudo
Chief Executive Officer
David Solomon
Chief Financial Officer
Torsten Hombeck
Chief Operating Officer/Director
Clive Richardson
Vice President
Nigel Hernandez
Director
David Byrne
Director
Peter Feldschreiber
Director
Michael Grissinger
Director
Robert Ward
Director
Donald Williams
Non-Executive Director
James Hill
Non-Executive Director
Stuart Ungar
No Data
  • All
  • Financials
  • Insiders
More
About AKTX
Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. The Company’s lead product candidate, nomacopan inhibits both terminal complement activation and leukotriene B4, or LTB4. It inhibits terminal complement activation by tightly binding to C5 and preventing its cleavage and activation by complement.

Webull offers kinds of Akari Therapeutics PLC (ADR) stock information, including NASDAQ:AKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AKTX stock methods without spending real money on the virtual paper trading platform.